# Sunshine Lake Pharma Co., Ltd. clinical trials: 83 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 83 trials with Sunshine Lake Pharma Co., Ltd. as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Sunshine Lake Pharma Co., Ltd.: 83 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/sunshine-lake-pharma-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 83
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 25 newest of 83, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07891377 | HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies | Sunshine Lake Pharma Co., Ltd. | Phase 2 | Not yet recruiting | Chemotherapy-induced Anemia, Non-Myeloid Malignancy | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891377) |
| September 17, 2026 | NCT07824934 | HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Recruiting | Advanced Malignant Solid Tumors | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824934) |
| August 18, 2026 | NCT07771140 | A Phase I Clinical Trial to Evaluate HECN30227 Injection in Healthy Subjects and Subjects With Chronic Hepatitis B | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Recruiting | HBV Infection | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771140) |
| May 15, 2026 | NCT07588646 | Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Idiopathic Pulmonary Fibrosis | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588646) |
| January 29, 2026 | NCT07376200 | Single-ascending Dose Study of HEC-151 Injection | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Recruiting | Healthy Adult Male | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376200) |
| January 14, 2026 | NCT07341672 | A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole... | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Not yet recruiting | Healthy Adult Subject | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341672) |
| October 7, 2025 | NCT07211165 | Clinical Study on the Mass Balance of Clifutinib | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Healthy Adult Male | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211165) |
| August 3, 2025 | NCT07102251 | A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Recruiting | Healthy Subjects | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07102251) |
| August 1, 2025 | NCT07099118 | A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Recruiting | Non - Alcoholic Steatohepatitis | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07099118) |
| July 24, 2025 | NCT07082842 | Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF | Sunshine Lake Pharma Co., Ltd. | Phase 3 | Recruiting | Idiopathic Pulmonary Fibrosis (IPF) | 472 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082842) |
| August 18, 2023 | NCT05998304 | ADME Study of \[14C\] Yiqibuvir in Healthy Male Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05998304) |
| April 7, 2023 | NCT05802862 | A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With... | Sunshine Lake Pharma Co., Ltd. | Phase 3 | Completed | Diabetes | 414 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05802862) |
| October 19, 2022 | NCT05586074 | HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML | Sunshine Lake Pharma Co., Ltd. | Phase 3 | Recruiting | Leukemia, Acute Myeloid (AML) | 324 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05586074) |
| October 12, 2022 | NCT05576298 | A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin... | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Type 2 Diabetes | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05576298) |
| August 17, 2022 | NCT05504876 | Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114 | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Healthy Subjects | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05504876) |
| August 11, 2022 | NCT05497674 | Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Type 2 Diabetes Mellitus | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05497674) |
| August 8, 2022 | NCT05492630 | Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Diabetic Nephropathy | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05492630) |
| July 21, 2022 | NCT05468346 | Study on the Body Mass Balance and Biotransformation of \[14C\]-HEC585 | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Healthy Volunteer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05468346) |
| July 14, 2022 | NCT05459285 | A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Type 2 Diabetes | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05459285) |
| July 12, 2022 | NCT05454098 | Clifutinib Food Effect Study in Healthy Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Acute Myeloid Leukemia in Children | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05454098) |
| July 11, 2022 | NCT05451602 | HEC169096 in Participants With Advanced Solid Tumors | Sunshine Lake Pharma Co., Ltd. | Phase 1/2 | Terminated | Advanced Solid Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05451602) |
| July 6, 2022 | NCT05446233 | ADME Study of \[14C\] Antaitavir Hasophate in Healthy Male Subjects | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Healthy Male Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05446233) |
| June 22, 2022 | NCT05427682 | A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Pyroglutamate Rongliflozin Capsules in Subjects With Mild and Moderate... | Sunshine Lake Pharma Co., Ltd. | Phase 1 | Completed | Diabetes Mellitus, Type 2 | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05427682) |
| May 31, 2022 | NCT05397379 | A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis | Sunshine Lake Pharma Co., Ltd. | Phase 2 | Completed | Non-Alcoholic Steatohepatitis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05397379) |
| May 27, 2022 | NCT05395416 | Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C | Sunshine Lake Pharma Co., Ltd. | Phase 2/3 | Completed | Chronic HCV Infection | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05395416) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 61 |
| Phase 1/2 | 7 |
| Phase 2 | 8 |
| Phase 2/3 | 2 |
| Phase 3 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 61 |
| Recruiting | 11 |
| Terminated | 6 |
| Withdrawn | 2 |
| Not yet recruiting | 2 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Idiopathic Pulmonary Fibrosis | 7 |
| Hepatitis C, Chronic | 7 |
| Diabetes Mellitus, Type 2 | 6 |
| Non-alcoholic Fatty Liver Disease | 5 |
| Hepatitis B, Chronic | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Depressive Disorder, Major | 3 |
| Esophageal Neoplasms | 2 |
| Sleep Initiation and Maintenance Disorders | 2 |
| Diabetes Mellitus | 1 |
| Renal Insufficiency | 1 |
| Pancreatic Neoplasms | 1 |
| Diabetic Nephropathies | 1 |
| Renal Insufficiency, Chronic | 1 |
| Influenza, Human | 1 |
| Asthma | 1 |
| Gout | 1 |
| Recurrence | 1 |
| Esophageal Squamous Cell Carcinoma | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Parkinson Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
- [Breweries in the United States](https://specstream.ai/data/businesses/breweries/united-states)
- [Bookkeeping firms in the United States](https://specstream.ai/data/businesses/bookkeeping-firms/united-states)
- [Blinds and shades companies in the United States](https://specstream.ai/data/businesses/blinds-and-shades-companies/united-states)
- [Beverage suppliers in the United States](https://specstream.ai/data/businesses/beverage-suppliers/united-states)
